图片来源:国家药品监督管理局 免疫治疗不止有"PD-1",还有"PD-L1" Ⅲ期肺癌,并不是无路可走 01 单纯放疗仍为指南推荐 02 不断更新的靶向治疗 03 联合免疫带来更多选择 小编小结 责任编辑:觅健科普君 参考来源: [1] https://en./wiki/PD-1_and_PD-L1_inhibitors [2] CSCO原发性肺癌诊疗指南2019版 [3] Goldstraw P, et al. Journal of Thoracic Oncology, 2016, 11(1): 39-51. [4] Jhanelle E. Gray et al. Brief report: Three-year overall survival with Durvalumab after chemoradiotherapy in Stage III NSCLC - Update from PACIFIC. https:///10.1016/j.jtho.2019.10.002. [5] NCCN Clinical Practice Guidelines in Oncology, Non-Small Cell Lung Cancer, Version 3.2019 |
|